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Association Between Plasma Neutrophil Gelatinase-Associated
Lipocalin and Cardiac Disease Hospitalizations and Deaths in Older
Women
James J. H. Chong, PhD, FRACP, MBBS; Richard L. Prince, BSc, MB ChB, MD, FRACP, MRCP; Peter L. Thompson, AM, MBBS, MD, FRACP,
FACP, FACC, MBA; Sujitha Thavapalachandran, MBBS, FRACP; Esther Ooi, BSc (Hons), PhD; Amanda Devine, PhD, BAppSc, GradDipEd,
BEd (Hons); E. E. M. Lim, MBBS, FRACP, FRCPA, MAACB; Elizabeth Byrnes, BAppSc, Grad Dip Ed, MAACB, MLabMed; Germaine Wong,
MBBS, PhD, FRACP; Wai H. Lim, MBBS, PhD, FRACP; Joshua R. Lewis, BSc (Hons), PhD
Background-—Neutrophil gelatinase-associated lipocalin (NGAL) or lipocalin 2 may promote atherosclerosis and plaque instability
leading to increased risk of cardiac events. We investigated the relationships between plasma NGAL, cardiovascular disease
biomarkers, and long-term cardiac events.
Methods and Results-—The study population consisted of 1131 ambulant older white women (mean age 75 years) without clinical
coronary heart disease (CHD) and measures of plasma NGAL in the Perth Longitudinal Study of Ageing Women with 14.5-year CHD
and heart failure hospitalizations or death (events) captured using linked records. Over 14.5 years, 256 women had CHD events,
while 118 had heart failure events. Per SD increase in log-transformed NGAL there was a 35% to 37% increase in relative hazards
for CHD and heart failure events in unadjusted analyses, which remained significant after adjustment for conventional risk factors
for CHD events (hazard ratio 1.29, 95% CI 1.13–1.48, P<0.001) but not heart failure (P>0.05). Women in the highest 2 quartiles of
NGAL had higher relative hazards for CHD events compared with women in the lowest quartile hazard ratio 1.61, 95% CI 1.08–
2.39, P=0.019 and hazard ratio 1.97, 95% CI 1.33–3.93, P=0.001, respectively. These associations were independent of high-
sensitivity cardiac troponin I, homocysteine, and estimated renal function. NGAL correctly reclassified 1 in 4 women who sustained
a CHD event up in risk and 1 in 10 women without CHD events down in risk.
Conclusions-—NGAL was associated with increased risk of long-term CHD events, independent of conventional risk factors and
biomarkers. These findings provide mechanistic insight into the role of NGAL with cardiac events. ( J Am Heart Assoc. 2019;8:
e011028. DOI: 10.1161/JAHA.118.011028)
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A n increasing number of inflammation-related proteins arebeing assessed as biomarkers of coronary artery disease
(CAD) progression and risk prediction. The data from recent
studies point to neutrophil gelatinase-associated lipocalin
(NGAL) as a previously underappreciated factor in CAD
development and progression. NGAL belongs to the lipocalin
superfamily, proteins that specialized in binding and transport-
ing small hydrophobic molecules, and exists in 3 molecular
forms in blood and urine: a monomer, a homodimer, and a
heterodimer, covalently bound with matrix metalloproteinase-
9. NGAL is highly expressed in kidney tubule cells in response to
injury and hence, a knownmarker of acute kidney injury. Recent
evidence from both mouse and human studies demonstrates
that NGAL is highly expressed in cardiomyocytes and
atherosclerotic plaques.1–4 In these sites, NGAL modulates a
range of cellular responses, such as proliferation,
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differentiation, and apoptosis1 associated with vascular func-
tion and atherosclerosis5 and also in vascular remodeling.6,7
NGAL has also been found to be associated with obesity in
humans, in particular, cholesterol mobilization to peripheral
tissues.8 Studies of animal diet–induced obesity suggest that
NGAL may be an important marker of inflammation leading to
endothelial dysfunction and elevated blood pressure.9
To investigate these relationships further, we analyzed the
predictive role of NGAL on clinical outcomes in a large cohort
study of older women. In addition, to better understand the
potential pathophysiological role of plasma NGAL in cardio-
vascular disease, we studied the relationship between NGAL
and high-sensitivity cardiac troponin I (hs-cTnI) , a validated
marker of acute coronary syndrome and mortality previously
studied in this and other populations.10,11 Second, given the
evidence that elevated homocysteine promotes inflammatory
monocyte differentiation, activates pro-inflammatory path-
ways, and accelerates the progression of atherosclerosis,12
we also investigated this potential pathological pathway.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. This material will be
available on request and approval at the Perth Longitudinal
Study of Ageing Women website.13
Ethics Statement
The Human Ethics Committee of the University of Western
Australia approved the study and written informed consents
were obtained from all participants. Human ethics approval
for the use of linked data for the project was provided by
the Human Research Ethics Committee of the
Western Australian Department of Health, project number
#2009/24.
Study Population
The participants were recruited in 1998 to a 5-year
prospective, randomized, controlled trial of oral calcium
supplements to prevent osteoporotic fractures, the CAIFOS
(Calcium Intake Fracture Outcome) study as described
previously.14 Briefly, 1500 women were recruited from the
Western Australian general population by mail using the
electoral roll. All participants were ambulant with an
expected survival beyond 5 years and were not receiving
any medication (including hormone replacement therapy)
known to affect bone metabolism. Baseline disease burden,
cardiovascular disease risk, and medications were compara-
ble between these participants and the general population of
similar age, although these participants were more likely to
be from higher socioeconomic groups.14 At the conclusion of
CAIFOS, participants were subsequently included in addi-
tional follow-up studies for an additional 10 years as the
Perth Longitudinal Study of Aging in Women (PLSAW)
http://www.lsaw.com.au. The randomized controlled trial
was commenced and completed before the introduction of
clinical trial registries; hence the trial was retrospectively
registered in the Australian New Zealand Clinical Trials
Registry ACTRN12615000750583.
Baseline Risk Factors
Baseline medical history including the presence of diabetes
mellitus, hypertension, smoking history (current smokers/
former smokers or nonsmokers), and medications was
obtained from all participants as described previously.11
Biochemistry
Venous blood samples were collected between 0830 and
1030 hours after overnight fasting at baseline (1998) and
were stored at 80°C until assessment. Total cholesterol,
high-density lipoprotein cholesterol (HDLC), and triglyceride
concentrations were determined using a Hitachi 917 auto
analyzer (Roche Diagnostics). Low-density lipoprotein choles-
terol was calculated using Friedewald’s method.15 hs-cTnI was
measured in 2013 in baseline serum stored at 80°C using
the Abbott ARCHITECT i2000SR STAT hs-TnI assay as
described previously.11 Plasma that had not been previously
defrosted was used to measure NGAL using a 2-step
chemiluminescent microparticle monoclonal immunoassay
Clinical Perspective
What Is New?
• Neutrophil gelatinase-associated lipocalin is a recently
identified marker of inflammation.
• Older women with elevated neutrophil gelatinase-associated
lipocalin levels had a higher risk of coronary heart disease
hospitalization and death, independent of conventional risk
factors and other cardiac biomarkers.
What Are the Clinical Implications?
• This association between elevated neutrophil gelatinase-
associated lipocalin and coronary heart disease events was
in addition to cardiac troponin I levels and may represent a
future risk stratification tool to identify older patients with
atypical symptoms who will benefit most from invasive
coronary angiography.
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on an automated platform (Abbott Diagnostics, Longford,
Ireland). The interassay coefficient of variation over a 3-week
period was 6.07% and 2.63% at concentrations of 21 and
1194 ng/L, respectively. Baseline creatinine was measured
using an isotope dilution mass spectrometry traceable Jaffe
kinetic assay in 2003 on a Hitachi 917 analyzer (Roche
Diagnostics GmbH, Mannheim Germany). Estimated glomeru-
lar filtration rate (eGFR) using creatinine was calculated using
the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation. The plasma total L-homocysteine was measured
using a Fluorescence Polarization Immuno-assay on an Abbott
IMx Analyzer (Abbott Laboratories, Abbott Park, IL). The
interassay coefficient of variation for homocysteine measure-
ment was <5%. The total L-homocysteine includes free
monomeric homocysteine, free dimeric homocysteine, pro-
tein-bound forms, and mixed dimeric low molecular mass
forms.
Cardiac Disease Hospitalizations and Deaths
The first episode of cardiac hospitalization or death was
identified using data from the Hospital Morbidity Data
Collection and WA Deaths Registry, linked via the Western
Australian Data Linkage System as described previously.11
Statistical Analysis
Baseline data are presented as either meanSD, median
and interquartile range (IQR), or number and (%) where
appropriate. Non-normally distributed baseline factors includ-
ing NGAL were transformed using their natural logarithm (ln-
NGAL) to reduce skewness and improve approximation of
normal distribution. The associations between baseline
covariates on ln-NGAL were determined using univariate
linear regression analysis. Forward stepwise multivariable
regression analysis of variables significant in the univariate
analysis was used to determine variables independently
associated with NGAL. As NGAL, homocysteine, and hs-TnI
were not normally distributed, Spearman’s correlations were
undertaken for unadjusted analyses. Unadjusted and multi-
variable-adjusted Cox proportional hazards regression anal-
yses were undertaken to test the association of NGAL with
coronary heart disease (CHD) hospitalizations and deaths.
No violations of the Cox proportional hazards assumptions
were detected. Multivariable-adjustments included the vari-
ables used in the Framingham risk equation (model 1: age,
body mass index [BMI], current smoker, prescription of
antihypertensive medication, systolic blood pressure, history
of diabetes mellitus) plus treatment code (calcium or
placebo). Further analyses including replacing BMI with
Figure 1. Overview of the study participants. All participants had hospital (1980–2013) and mortality
(1998–2013) records available from the Western Australian Data linkage system. CAD indicates coronary
artery disease.
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HDLC and total cholesterol (model 2) as well as further
adjustments for potential mediators of disease including
estimated glomerular filtration rate (eGFR), hs-c-TnI, and
homocysteine were also undertaken. Additionally, given the
advanced age of these women, we also performed compet-
ing-risks analyses based on Fine and Gray’s proportional
subdistribution hazards model16 to account for the compet-
ing risk of noncardiac mortality (all-other causes of death).
The discriminative performance were calculated using the
Harrell’s C-statistic17 with discrimination considered to be
poor (<0.6), moderate (0.6–0.8), or good (≥0.8). Because of
the low sensitivity of these analyses, net reclassification and
integrated discrimination improvement indices were also
performed.18 In order to do so, the first model included all
the variables in the general Framingham risk model using
BMI and treatment code (referent model), and the second
model included all variables in the general Framingham
cardiovascular risk model using BMI plus treatment code
with the addition of NGAL (ln-NGAL, quartiles of NGAL, or
median NGAL). The calibration was tested by separating
participants into deciles of predicted risk compared with the
actual risk. For net reclassification improvement, we used a
category-free approach (no P value applied) as there are no
suggested cut points for cardiovascular risk in the elderly.
All analyses were undertaken using IBM SPSS Statistics
Version 21 (2012, IBM Corp, Armonk, NY), STATA (version
Table 1. Baseline Characteristics of the Cohort by Quartiles of NGAL
Baseline Characteristics Whole Cohort (n=1131) Quartile 1 (n=280) Quartile 2 (n=284) Quartile 3 (n=284) Quartile 4 (n=283)
NGAL, median [IQR], ng/mL 76 [62–95] 54 [46–58] 69 [65–72] 85 [80–89] 113 [102–136]
Age, meanSD, y 75.22.7 74.82.75† 75.12.6† 75.32.9† 75.82.8†
BMI, meanSD, kg/m2 27.04.7 25.74.3† 26.64.5† 27.04.3† 28.95.0†
Smoking history
Never, N (%) 708 (62.9) 175 (62.7) 181 (64.0) 175 (62.3) 177 (62.5)
Previous, N (%) 413 (36.7) 102 (36.6) 101 (35.7) 104 (37.0) 106 (37.5)
Current, N (%) 5 (0.4) 2 (0.7) 1 (0.4) 2 (0.7) 0 (0.0)
Diabetes mellitus, N (%) 61 (5.4) 16 (5.7) 10 (3.5) 12 (4.2) 23 (8.1)
Antihypertensive medication, N (%) 476 (42.1) 91 (32.5)† 110 (38.7)† 117 (41.2)† 158 (55.8)†
Statin medication, N (%) 186 (16.4) 44 (15.7) 46 (16.2) 47 (16.5) 49 (17.3)
Low-dose aspirin, N (%) 201 (17.8) 42 (15.0) 46 (16.2) 58 (20.4) 55 (19.4)
Alcohol intake, median [IQR], g/d 1.9 [0.3–10.1] 2.8 [0.3–11.9]† 2.1 [0.3–11.3]† 2.1 [0.3–10.0]† 1.1 [0.3–6.2]†
Exercise, median [IQR], h/wk 4.0 [1.0–7.0] 4.0 [2.0–7.0]† 4.0 [1.0–8.0]† 4.0 [0.3–7.0]† 3.0 [0.0–6.0]†
Blood pressure
SBP, meanSD, mm Hg 13818 13818 13819 13719 13718
DBP, meanSD, mm Hg 7311 7312 7311 7311 7312
MAP, meanSD, mm Hg 9512 9512 9512 9412 9412
Lipid profiles (n=807)
Total cholesterol, meanSD, mg/dL 22743 22547 22540 23441 22542
LDLC, meanSD, mg/dL 14339 14041 14236 15038 14139
HDLC, meanSD, mg/dL 5615 6015† 5615† 5613† 5315†
Triglycerides, meanSD, mg/dL 13763 12356† 12960† 14162† 15470†
Cardiovascular biomarkers
hs-cTnI, median [IQR], pg/mL 4.6 [3.6–6.1] 4.1 [3.4–5.4]† 4.4 [3.6–5.9]† 4.7 [3.7–6.4]† 5.1 [4.0–6.5]†
Homocysteine, median [IQR], lmol/L* 11.3 [9.3–13.5] 9.9 [8.5–12.1]† 10.7 [8.8–13.1]† 11.9 [9.8–14.2]† 12.5 [10.6–15.4]†
eGFR, meanSD, mL/min per 1.73 m2 66.313.0 72.310.6† 68.311.3† 64.312.6† 60.613.0†
Results are meanSD or number and (%). BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDLC, high-density lipoprotein
cholesterol; hs-cTnI, high-sensitivity cardiac troponin I; IQR, interquartile range; LDLC, low-density lipoprotein cholesterol; MAP, mean arterial pressure; NGAL, neutrophil gelatinase-
associated lipocalin; SBP, systolic blood pressure.
*Measured in 905 women.
†Significant across group differences using univariate ANOVA, x2 test or Kruskal-Wallis test where appropriate.
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13; StataCorp LP, College Station, TX), or SAS (Version 9.4;
SAS Institute Inc, Chicago, IL). P values of <0.05 in 2-tailed
testing were considered statistically significant.
Results
Baseline Characteristics
Participant selection is outlined in Figure 1. To investigate the
associations and predictive utility of NGAL, we excluded these
114 individuals with prevalent CHD at baseline from all
subsequent analysis. NGAL levels were significantly higher in
the excluded cohort of 114 women with prevalent CHD
compared with those included in the study cohort (82.3 [IQR
66.1–101.8] versus 75.9 [IQR 61.5–94.0], P=0.042). Baseline
characteristics of the remaining 1131 older women included
in the study are presented in Table 1.
Correlations Between Plasma NGAL and Baseline
Variables
The correlations between ln-NGAL levels and these demo-
graphic, clinical, lifestyle, and laboratory variables are shown in
Table 2. Using forward stepwise linear regression, the most
parsimonious model for ln-NGAL that explained 18.6% of the
circulating levels included eGFR (P<0.001), BMI (P<0.001), ln-
homocysteine (P<0.001), age (P=0.004), and HDLC (P=0.016).
NGAL Levels and CHD Events
Over 14.5 years, 256/1131 (22.6%) women sustained CHD
hospitalization or death. For every 1 SD increase in ln-NGAL,
there was a 33% increase in the relative hazards for CHD
hospitalizations or death after adjusting for age and treatment
(hazard ratio [HR] 1.33, 95% CI 1.18–1.51, P<0.001). This
estimate remained similar after adjusting for conventional
cardiovascular risk factors used in the Framingham risk
equations (Table 3). Using a quartile approach, the relation-
ship between baseline NGAL and CHD hospitalization and
death is shown in Figure 2, with the adjusted HR presented in
Table 4. Compared with those in the lowest quartile of NGAL,
those in the highest 2 quartiles had increased relative hazards
for CHD hospitalizations or deaths in unadjusted analysis and
multivariable-adjusted models. Similar results were seen
when replacing the BMI with total cholesterol and HDLC in
the subset of 807 women with these data available (Table 4).
NGAL Levels and Heart Failure Events
Over 14.5 years, 118/1131 (10.4%) women sustained HF
hospitalization or death. For every 1 SD increase in ln-NGAL,
there was a 30% increase in the relative hazards for HF
hospitalizations or death after adjusting for age and treatment
(HR 1.30, 95% CI 1.08–1.56, P=0.005), which was no longer
statistically significant (P=0.060) after adjusting for conven-
tional cardiovascular risk factors (Table 3). Using a quartile
approach, the relationship between baseline NGAL and HF
hospitalization and death is shown in Figure 2. The values for
the HRs are shown in Table 4. Compared with those in the
lowest quartile of NGAL, those in the fourth quartile had
increased relative hazards for HF hospitalizations or deaths in
unadjusted analysis but not in multivariable-adjusted models
(Table 4). Similar results were seen when replacing the BMI
with total cholesterol and HDLC in the subset of 807 women
with these data available (Table 4).
Table 2. Correlations and Multivariate Associations Between
ln-NGAL, Clinical Variables, and Cardiac Biomarkers
Univariate Model Multivariable Model
r P Value Standardized b P Value
Age, y 0.142 <0.001 0.104 0.004
BMI, kg/m2 0.267 <0.001 0.213 <0.001
Diabetes mellitus
(yes)
0.069 0.021
Antihypertensive
medications (yes)
0.175 <0.001
Statin medications
(yes)
0.003 0.926
Low-dose aspirin
(yes)
0.046 0.120
Systolic blood
pressure, mm Hg
0.030 0.327
Diastolic blood
pressure, mm Hg
0.016 0.604
Current smoking
(yes)
0.016 0.580
Total cholesterol,
mg/dL
0.025 0.470
High-density
lipoprotein
cholesterol, mg/dL
0.157 <0.001 0.091 0.016
Low-density
lipoprotein
cholesterol, mg/dL
0.030 0.401
Triglycerides, mg/dL 0.174 <0.001
eGFR, mL/min per
1.73 m2
0.320 <0.001 0.194 <0.001
Ln-high-sensitivity
cardiac troponin I
0.160 <0.001
Ln-homocysteine 0.284 <0.001 0.144 <0.001
Multivariable model r2=0.186. BMI indicates body mass index; eGFR, estimated
glomerular filtration rate; NGAL, neutrophil gelatinase-associated lipocalin.
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NGAL Levels and Cardiac Risk Prediction
As circulating NGAL levels were not associated with HF events
in multivariable-adjusted models, no further analyses were
performed to determinewhether the addition of NGAL improved
risk prediction in addition to conventional risk factors. To study
the effects of NGAL as a risk predictor for CHD, we compared it
individually with conventional risk factors used in the
Figure 2. Kaplan–Meier hazard plots for CHD (n=256) and HF hospitalizations and deaths (n=118) by quartiles of NGAL, blue line quartile 1
(<61.5 ng/mL), green line quartile 2 (61.5–75.8 ng/mL), beige line quartile 3 (75.9–94.8 ng/mL), and purple line quartile 4 (≥94.9 ng/mL).
CHD indicates coronary heart disease; HF, heart failure; NGAL, neutrophil gelatinase-associated lipocalin.
Table 3. Multivariable-Adjusted HR for Cardiac Events Per SD Increase in the Natural Logarithm of Circulating NGAL
Coronary Heart Disease Events (n=256) Heart Failure Event (n=118)
HR (95% CI) P Value HR (95% CI) P Value
Model 1 (n=1131)* 1.29 (1.13–1.48) <0.001 1.21 (0.99–1.48) 0.060
+eGFR 1.25 (1.07–1.45) 0.004 1.30 (1.04–1.63) 0.019
+ln-hs-cTnI 1.27 (1.11–1.46) 0.001 1.18 (0.97–1.44) 0.106
+ln-homocysteine 1.21 (1.03–1.42) 0.027 1.11 (0.88–1.40) 0.379
+eGFR, ln-hs-cTnI,
and ln–homocysteine
1.21 (1.02–1.44) 0.032 1.17 (0.91–1.51) 0.232
Model 2 (n=807)† 1.49 (1.29–1.53) <0.001 1.22 (0.98–1.52) 0.076
+eGFR 1.37 (1.16–1.62) <0.001 1.26 (0.98–1.61) 0.066
+ln-hs-cTnI 1.40(1.20–1.64) <0.001 1.45 (1.20–1.74) 0.133
+ln-homocysteine 1.35 (1.13–1.62) 0.001 1.14 (0.54–2.72) 0.305
+eGFR, ln-hs-cTnI and
ln-homocysteine
1.34 (1.11–1.62) 0.003 1.17 (0.89–1.54) 0.249
Cox proportional hazard regression models were adjusted for conventional cardiovascular risk factors (Model 1 including; age, BMI, current smoking, systolic blood pressure,
prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo] or Model 2 including; age, total cholesterol, high-density lipoprotein
cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo]). BMI
indicates body mass index; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I; NGAL, neutrophil gelatinase-associated
lipocalin.
*Homocysteine was measured in 905 women.
†Homocysteine was measured in 700 women.
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Framingham Risk Score (Table 5). Ln-NGAL alone had poor
discrimination quantified by the area under the receiver
operating characteristic curve (c-statistic) for CHD (0.594,
95% CI 0.558–0.629). The addition of NGAL did not improve the
C-statistic for 14.5-year cardiac events compared with con-
ventional cardiovascular risk factors. However, newer mea-
sures of discrimination such as the Net Reclassification Index
and the Integrated Discrimination Index suggested that the
addition of NGAL may lead to substantial improvements. This
was particularly evident inmodels incorporating HDLC and total
cholesterol, with large proportions of women having a CHD
eventmoved correctly up in risk andwomenwho did not sustain
a CHD event moved down in risk (Table 5).
Putative Pathophysiological Mechanisms of NGAL
With Cardiac Outcomes
Given the lack of information on the mechanisms of adverse
effects of circulating NGAL on coronary atherosclerosis, we
sought to investigate whether NGAL was acting as a surrogate
marker of kidney function (eGFR), cardiac inflammation (homo-
cysteine), andmyocardial ischemia (hs-cTnI)orwas independent
of these markers of cardiovascular disease by including these
biomarkers individually or collectively into the multivariable-
adjusted models (Table 6). The Kaplan–Meier hazard plots for
CHDandHFhospitalizations anddeaths separatedbyaboveand
below the median NGAL and hs-cTnI are presented in Figure 3.
Table 4. Multivariable-Adjusted HR for Cardiac Events by Quartile of NGAL After Adjustment of Other Risk Factors
Number of Events (%)
Model 1*
HR (95% CI) P Value
Model 2*
HR (95% CI) P Value
Whole cohort (n=1131)
CHD events (n=256)
Quartile 1 (<61.5 ng/mL) 44 (15.7) 1.00 (referent) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 48 (16.9) 1.02 (0.68–1.54) 0.909 1.03 (0.67–1.59) 0.887
Quartile 3 (75.9–94.8 ng/mL) 72 (25.4) 1.62 (1.11–2.35) 0.012 1.61 (1.08–2.39) 0.019
Quartile 4 (≥94.9 ng/mL) 92 (32.5) 2.14 (1.49–3.08) <0.001 1.97 (1.33–2.93) 0.001
P for trend <0.001 <0.001
Heart failure events (n=118)
Quartile 1 (<61.5 ng/mL) 22 (7.9) 1.00 (referent) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 27 (9.5) 1.13 (0.65–1.99) 0.664 1.22 (0.66–1.91) 0.528
Quartile 3 (75.9–94.8 ng/mL) 24 (8.5) 1.01 (0.57–1.81) 0.971 1.01 (0.54–1.88) 0.985
Quartile 4 (≥94.9 ng/mL) 61 (15.9) 1.97 (1.17–3.30) 0.002 1.65 (0.92–2.96) 0.093
P for trend 0.004 0.079
Those with lipids (n=807)
CHD events (n=170)
Quartile 1 (<61.5 ng/mL) 24 (12.0) 1.00 (referent) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 32 (15.2) 1.23 (0.71–1.60) 0.442 1.28 (0.73–2.23) 0.384
Quartile 3 (75.9–94.8 ng/mL) 52 (25.2) 2.16 (1.33–3.50) 0.002 2.15 (1.29–3.58) 0.003
Quartile 4 (≥94.9 ng/mL) 62 (32.6) 2.81 (1.75–4.52) <0.001 2.64 (1.59–4.38) <0.001
P for trend <0.001 <0.001
Heart failure events (n=83)
Quartile 1 (<61.5 ng/mL) 15 (7.5) 1.00 (referent) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 20 (9.5) 1.18 (0.61–2.31) 0.624 1.28 (0.63–2.60) 0.494
Quartile 3 (75.9–94.8 ng/mL) 19 (9.2) 1.16 (0.59–2.28) 0.669 1.31 (0.64–2.66) 0.462
Quartile 4 (≥94.9 ng/mL) 29 (15.3) 1.88 (1.00–3.53) 0.049 1.63 (0.82–3.23) 0.161
P for trend 0.034 0.167
CHD indicates coronary heart disease; HR, hazard ratio; NGAL, neutrophil gelatinase-associated lipocalin.
*Cox regression models were adjusted for conventional cardiovascular risk factors (Model 1 including age, and treatment code [calcium or placebo] or Model 2 including age, BMI or total
cholesterol and high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium
or placebo]).
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For all analyses with the CHD outcome with the biomarkers
individually and NGAL, both remained significantly associated
with CHD outcomes. When all 3 biomarkers were added, NGAL
remained significantly associated with CHD events.
Further Analyses
Interaction testing between NGAL and cardiovascular risk factors
forCHDevents is presented in Table 7. This testing suggested that
NGAL may be more strongly associated with CHD events when
HDLC is normal. To explore the extent of reverse causality bias, we
excluded cardiac events occurring within the first 2 years as well
as undertaking competing risks regression analyses with deaths
as a competing risk, both of which did not substantially alter the
findings (Table 8). Additionally, we tested the association of NGAL
with myocardial infarctions and/or CHD death (hard CHD) that
occurred in 172/1131 (15.2%) of the women. Per SD increase in
ln-NGAL was associated with increased relative hazards of hard
CHD (unadjusted HR 1.39, 95% CI 1.20–1.61, P<0.001 and
multivariable-adjusted HR 1.30, 95% CI 1.10–1.53, P=0.002).
Similarly, in the quartile analysis, women in the highest quartile of
NGAL had the highest relative hazards of hard CHD (quartile 4
versus quartile 1 unadjusted HR 2.28, 95%CI 1.49–3.50, P<0.001
andmultivariable-adjusted HR 1.84, 95% CI 1.16–2.94, P=0.010).
Discussion
Toour knowledge, this is thefirst prospective study to investigate
the associationsbetweenplasmaNGALand the cardiac ischemia
biomarker hs-cTnI. Additionally, we investigated NGAL as a
predictor of CHD andHF in older womenwith no previous clinical
CHD. Higher levels of plasma NGAL were independently
associated with a worse CHD risk profile, elevated levels of hs-
cTnI and homocysteine, and a 2- to 3-fold increase in the relative
hazards for CHD hospitalizations and death in the highest
quartile of NGAL women compared with those in the lowest
quartile. These findings are consistent with other prospective
cohort studies in middle-aged19 and older community-dwelling
adults20 that have shown independent associations between
NGAL and CHD events. These associations were robust and
independent of hs-TnI, homocysteine, and eGFR. To our knowl-
edge, this is the first study to show that NGAL is associated with
CHD events, independent of hs-TnI.
All women had detectable NGAL, with levels correlating
with hs-cTnI. Cardiac troponin levels are now the standard of
care to identify myocyte necrosis and for cardiovascular risk
stratification. Serum cardiac troponin levels directly relate to
the risk of future cardiovascular events in both young and
elderly populations and improve risk prediction in addition to
current established risk factors.11,21 Therefore, the establish-
ment of NGAL as a novel biomarker with added predictive
value above and beyond cardiac troponins has implications for
provision of cardiovascular care and associated health costs.
Similarly, NGAL levels correlated with homocysteine concen-
trations (r=0.3, P<0.001), supporting a previous report in a
small cohort of 141 patients who had advanced carotid
atherosclerotic lesions and who underwent carotid
endarterectomy for vascular repair, r=0.4, P<0.001.22 Taken
Table 5. Area Under the Curve, NRI, and IDI
c-Statistic P Value*
Category Free
NRI (95% CI)
Correctly
Reclassified
Higher (%)
Correctly
Reclassified
Lower (%) IDI P Value*
Model 1 (n=1131)
CHD events (n=256)
Conventional risk factors 0.625
+ln-NGAL 0.637 0.175 0.258 14.9 11.0 0.013 <0.001
+Quartiles of NGAL 0.641 0.135 0.329 23.2 9.8 0.017 <0.001
+Above the median NGAL 0.639 0.146 0.371 30.6 6.5 0.015 <0.001
Model 2 (n=807)
CHD events (n=170)
Conventional risk factors 0.637
+ln-NGAL 0.660 0.064 0.366 18.3 18.3 0.029 <0.001
+Quartiles of NGAL 0.662 0.078 0.451 31.7 13.4 0.029 <0.001
+Above the median NGAL 0.658 0.149 0.471 36.6 10.5 0.027 <0.001
BMI indicates body mass index; CHD, coronary heart disease; IDI, integrated discrimination improvement; NGAL, neutrophil gelatinase-associated lipocalin; NRI, net reclassification
improvement.
*Compared with conventional risk factors (Model 1 including age, BMI, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and
treatment code [calcium or placebo] or Model 2 including age, total cholesterol, high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of
antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo]).
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together, these findings suggest that a relationship between
NGAL and homocysteine exists and warrants further study.
While the women in our study did not have pre-existing
clinical CHD at baseline, NGAL was associated with several
traditional cardiovascular risk factors including age, hyper-
tension, renal impairment, and low HDL levels. Similar
findings were reported by Elneihoum et al,23 where plasma
levels of NGAL were higher in older hypertensive women
Table 6. Multivariable-Adjusted HR for Coronary Events by NGAL and Biomarkers of Potential Pathological Mechanisms*
Number of Events (%)
Model 1*
HR (95% CI) P Value Number of Events (%)
Model 2*
HR (95% CI) P Value
NGAL and hs-cTnI
↓NGAL and ↓hs-cTnI, n=319/229 42 (13.2) 1.00 (referent) 23 (10.0) 1.00 (referent)
↓NGAL and ↑hs-cTnI, n=239/171 49 (20.5) 1.57 (1.01–2.43) 0.043 31 (19.3) 1.92 (1.09–3.37) 0.026
↑NGAL and ↓hs-cTnI, n=240/177 49 (20.4) 1.51 (0.97–2.35) 0.069 32 (18.1) 1.76 (0.99–3.15) 0.056
↑NGAL and ↑hs-cTnI, n=322/219 115 (35.7) 2.72 (1.84–4.03) <0.001 81 (37.0) 3.73 (2.24–6.22) <0.001
NGAL and homocysteine
↓NGAL and ↓homocysteine, n=273/216 39 (14.3) 1.00 (referent) 30 (13.2) 1.00 (referent)
↓NGAL and ↑homocysteine, n=175/138 32 (18.3) 1.25 (0.77–2.03) 0.365 19 (13.8) 0.85 (0.46–1.56) 0.602
↑NGAL and ↓homocysteine, n=172/135 38 (22.1) 1.47 (0.92–2.34) 0.104 30 (22.4) 1.56 (0.93–2.63) 0.095
↑NGAL and ↑homocysteine, n=285/211 88 (30.9) 1.97 (1.32–2.94) 0.001 64 (30.3) 1.85 (1.17–2.95) 0.009
NGAL and chronic kidney disease
↓NGAL and no CKD, n=403/306 61 (15.1) 1.00 (referent) 38 (12.4) 1.00 (referent)
↓NGAL and CKD, n=100/80 22 (22.0) 1.54 (0.92–2.59) 0.102 16 (20.0) 1.56 (0.84–2.90) 0.161
↑NGAL and no CKD, n=290/205 66 (22.8) 1.57 (1.09–2.24) 0.014 45 (22.0) 1.78 (1.15–2.77) 0.010
↑NGAL and CKD, n=223/165 88 (39.5) 2.99 (2.14–4.18) <0.001 89 (39.4) 3.22 (2.11–4.92) <0.001
*Cox regression models were adjusted for conventional cardiovascular risk factors (Model 1 including age, and treatment code [calcium or placebo] or Model 2 including age, total
cholesterol, high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or
placebo]). ↓=Less than the median value and ↑ greater than or equal to the median value. CKD indicates chronic kidney disease; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I;
NGAL, neutrophil gelatinase-associated lipocalin.
*Homocysteine only measured in 905 women.
Figure 3. Kaplan–Meier hazard plots for CHD (n=256) and HF hospitalizations and deaths (n=118) by ↑ or ↓ median NGAL and ↑ or ↓ median
hs-TnI. Blue line=↓ median NGAL and ↓ median hs-TnI, green line=↑ median NGAL and ↓ median hs-TnI, beige line=↓ median NGAL and ↑ median
hs-TnI and purple line=↑ median NGAL and ↑ median hs-TnI. CHD indicates coronary heart disease; HF, heart failure; hs-TnI, high-sensitivity
cardiac troponin I; NGAL, neutrophil gelatinase-associated lipocalin.
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compared with younger normotensive individuals. We and
others have demonstrated the relationship between increased
circulating NGAL and high creatinine/reduced eGFR.24 In the
present study, the strongest relationship between NGAL and
CHD risk was seen in women with established cardiovascular
risk factors, suggesting that plasma NGAL provides additive
predictive value above cardiac troponin I in women at the
highest risk. This is demonstrated in Figure 3, showing that
women with elevated NGAL but not hs-TnI and vice versa had
similar long-term prognosis while women with elevated levels
of both had the highest CHD risk. Given that hs-cTnIs are
emerging as valuable markers of long-term cardiovascular risk
in people without a history of cardiovascular disease,25 these
findings are particularly noteworthy.
Regarding determination of clinical limits for NGAL levels
and associated cardiovascular risk assessment, there are
published reports using a variety of in-house or commercial
assays for quantification,20,26–28 but the agreement between
these assays and the specificity of these assays to detect
different circulating forms remains to be demonstrated. Given
these issues, we used 3 different models based on the
distribution with Framingham risk scores plus ln-NGAL (con-
tinuous), median NGAL, and quartiles of NGAL to provide similar
data to previous studies investigating broader composite
cardiovascular disease events or deaths.19,20 Similar to these
studies, we found modest improvements to the c-statistic;
however, in our study these were nonsignificant, presumably
because of the smaller sample size and fewer events. We did,
however, see relatively large improvements to reclassification
with the addition of NGAL to Framingham risk scores. The
discrepancy between the findings for the c-statistic and the net
reclassification may reflect previous observations that the use
of receiver operating characteristic may be less sensitive and
less clinically relevant than reclassification indices.29,30
Table 7. Age-Adjusted HR for CHD Events Per SD Increase in
ln-NGAL
Coronary Heart Disease Events
N (%) HR (95% CI), P Value*
P Value
Inter.
Framingham risk scores
<20% (n=577) 100 (17) 1.21 (0.98–1.49), 0.079 0.268
≥20% (n=513) 142 (28) 1.41 (1.20–1.65), <0.001
Age, y
<75 y (n=515) 100 (19) 1.38 (1.13–1.69), 0.002 0.788
≥75 y (n=616) 156 (25) 1.31 (1.12–1.53), 0.001
BMI
<25 kg/m2 (n=401) 80 (20) 1.29 (0.98–1.69), 0.067
25–29 kg/m2 (n=473) 102 (22) 1.45 (1.20–1.75), <0.001 0.479
≥30 kg/m2 (n=255) 74 (29) 1.12 (0.90–1.39), 0.317
Hypertension
No (n=496) 82 (17) 1.08 (0.85–1.37), 0.548 0.101
Yes (n=635) 174 (27) 1.38 (1.20–1.59), <0.001
Elevated total cholesterol
<200 mg/dL (n=194) 35 (18) 1.27 (0.93–1.74), 0.137 0.248
≥200 mg/dL (n=613) 135 (22) 1.57 (1.31–1.83), <0.001
Low HDLC
<60 mg/dL (n=514) 123 (24) 1.64 (1.37–1.95), <0.001 0.030
≥60 mg/dL (n=293) 47 (16) 1.14 (0.86–1.51), 0.360
Smoking history
Never (n=708) 143 (20) 1.29 (1.09–1.53), 0.003 0.837
Yes (n=418) 112 (27) 1.36 (1.14–1.64), 0.001
History of diabetes mellitus
No (n=1070) 238 (22) 1.34 (1.17–1.52), <0.001 0.830
Yes (n=61) 18 (30) 1.16 (0.78–1.73), 0.459
Lipid-lowering therapy
No (n=945) 214 (23) 1.32 (1.15–1.50), <0.001 0.091
Yes (n=186) 42 (23) 1.44 (1.02–2.04), 0.038
Low-dose aspirin
No (n=930) 200 (22) 1.35 (1.17–1.56), <0.001 0.523
Yes (n=201) 56 (28) 1.26 (0.98–1.61), 0.072
Physical activity
<median (n=538) 127 (24) 1.29 (1.09–1.53), 0.004 0.514
≥median (n=593) 129 (22) 1.37 (1.15–1.64), <0.001
eGFR <60 mL/min per 1.73 m2
Yes (n=323) 110 (34) 1.33 (1.10–1.61), 0.003 0.446
No (n=694) 127 (18) 1.18 (0.97–1.43), 0.085
hs-cTnI
<median (n=558) 91 (16) 1.38 (1.11–1.70), 0.004 0.442
≥median (n=562) 164 (29) 1.24 (1.06–1.44), 0.006
Continued
Table 7. Continued
Coronary Heart Disease Events
N (%) HR (95% CI), P Value*
P Value
Inter.
Homocysteine†
<median (n=445) 77 (17) 1.26 (0.99–1.61), 0.061 0.829
≥median (n=460) 120 (26) 1.30 (1.08–1.56), 0.005
BMI indicates body mass index; eGFR, estimated glomerular filtration rate; HDLC, high-
density lipoprotein cholesterol; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin
I; NGAL, neutrophil gelatinase-associated lipocalin.
*P value from age and treatment (calcium or placebo)-adjusted Cox regression. P value
per inter. from the interaction between per SD increase in ln-NGAL with baseline
variables with significance set at (P<0.1).
†Homocysteine was measured in a subset of 905 women.
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Circulating NGAL has been related to local production in
many tissues and thus may reflect local tissue inflammation.
To date the majority of human studies investigating the
association of circulating NGAL with heart disease have been
cross-sectional studies, in patients with pre-existing disease.
Such studies make causality harder to infer. Importantly,
these studies do suggest that NGAL may be related to the
presence and severity of CAD.3,23,27,31 Indeed, 2 prospective
studies of patients undergoing cardiac surgery for CAD have
shown that pre/postoperative plasma NGAL is independently
associated with all-cause mortality,28 cardiovascular deaths,
or subsequent cardiac events.26 In a prospective study of
younger men and women without a history of clinical
cardiovascular disease, plasma NGAL was independently
associated with 10-year cardiovascular outcomes and
modestly improved the c-statistic and net reclassification
when added to the Framingham risk scores.19 Daniels et al20
followed elderly men and women without a history of clinical
cardiovascular disease for a maximum of 16.2 years and
found that plasma NGAL was independently associated with
a composite end point of myocardial infarction, revascular-
ization, or cardiovascular disease death, providing incremen-
tal value to the well-established biomarkers N-terminal pro-
brain natriuretic peptide and C-reactive protein. It is
reassuring that the adjusted HR for the composite outcome
(HR 1.33) in this study was very similar to that seen in this
cohort (HR 1.29), suggesting that these findings may be
generalizable to other similarly aged populations. However,
before this present study, the association of NGAL with
markers of ongoing CAD, plaque rupture, or myocyte damage
(such as with cardiac troponin elevation) has not been
investigated.
The recent CANTOS trial showed that a human monoclonal
antibody targeting interleukin-1b lowered rates of recurrent
cardiovascular events in patients with myocardial infarction
and elevated high-sensitivity C-reactive protein, independent
of low-density lipoprotein cholesterol lowering.32 This has
reinvigorated discussions on direct roles for chronic inflam-
mation in CAD. Similarly, there may be a chronic inflammatory
role for NGAL. Indeed, NGAL is induced by interleukin-1b in
murine adipocytes,33 human hepatic stellate cells and
hepatocytes,34 vascular smooth muscle cells,35 and isolated
neonatal rat cardiomyocytes.36 Significantly, one study has
reported a close association between NGAL and high-
sensitivity C-reactive protein, with concomitant reductions in
both high-sensitivity C-reactive protein (40%) and NGAL
(32%) following 8-week treatment with rosiglitazone,8 an
insulin-sensitizer with interleukin-1b antagonism effects.37,38
However, it should be noted that this study was nonrandom-
ized and had no control group as well as a limited sample size.
Therefore, further investigations are needed in this area.
Aside from the role of NGAL in inflammation, studies
suggest that NGAL is involved in iron homeostasis. Given that
iron overload and deficiencies have been associated with
impaired cardiac function and hypercoagulation, NGAL may
therefore play a key role in development of certain cardiomy-
opathies. In addition, NGAL may play a role in regulating
aldosterone-mediated hypertension, with genetic inactivation
of NGAL in mice preventing mineralocorticoid-induced blood
pressure increases. Furthermore, in vitro studies suggest that
NGAL may influence the proliferation of fibroblasts. Given a
key role of proliferation, particularly by myofibroblasts, in the
mechanisms of remodeling, the proliferative effects of NGAL
may also be involved in pathological cardiac remodeling.
With an aging population, the proportion of elderly patients
undergoing percutaneous coronary intervention has increased
considerably.39 The elderly are also at higher risk for
Table 8. Multivariable-Adjusted Competing Risks Analysis
(Noncardiac Deaths) for Cardiac Events Per Quartile of NGAL
SHR (95% CI)* P Value
Whole cohort (n=1131)
CHD events (n=256)
Quartile 1 (<61.5 ng/mL) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 1.03 (0.67–1.59) 0.887
Quartile 3 (75.9–94.8 ng/mL) 1.61 (1.08–2.39) 0.019
Quartile 4 (≥94.9 ng/mL) 1.97 (1.33–2.93) 0.001
Heart failure events (n=118)
Quartile 1 (<61.5 ng/mL) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 1.22 (0.66–1.91) 0.528
Quartile 3 (75.9–94.8 ng/mL) 1.01 (0.54–1.88) 0.985
Quartile 4 (≥94.9 ng/mL) 1.65 (0.92–2.96) 0.093
Those with lipids (n=807)
CHD events (n=170)
Quartile 1 (<61.5 ng/mL) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 1.28 (0.73–2.23) 0.384
Quartile 3 (75.9–94.8 ng/mL) 2.15 (1.29–3.58) 0.003
Quartile 4 (≥94.9 ng/mL) 2.64 (1.59–4.38) <0.001
Heart failure events (n=83)
Quartile 1 (<61.5 ng/mL) 1.00 (referent)
Quartile 2 (61.5–75.8 ng/mL) 1.28 (0.63–2.60) 0.494
Quartile 3 (75.9–94.8 ng/mL) 1.31 (0.64–2.66) 0.462
Quartile 4 (≥94.9 ng/mL) 1.63 (0.82–3.23) 0.161
BMI indicates body mass index; CHD, coronary heart disease; NGAL, neutrophil
gelatinase-associated lipocalin; SHR, subdistribution hazard ratio.
*Models were adjusted for conventional cardiovascular risk factors (Model 1 including
age, BMI, current smoking, systolic blood pressure, prescription of antihypertensive
medications, diabetes mellitus, and treatment code [calcium or placebo] or Model 2
including age, total cholesterol, high-density lipoprotein cholesterol, current smoking,
systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus;
and treatment code [calcium or placebo]).
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procedure-related complications and peri-interventional mor-
tality following percutaneous coronary intervention, despite
appearing to derive significant benefits in terms of quality of
life.39,40 Furthermore, CHD screening investigations such as
CT coronary angiography and exercise stress tests are less
useful in this elderly population because of poor exercise
capacity and coronary artery calcification–related artifact.41
NGAL levels in addition to cTnI levels in elderly patients may
represent a future method to select elderly patients with
atypical symptoms who would benefit the most from invasive
coronary angiography.
This study has several limitations. First, blood samples were
frozen at 80°C for 15 years before measurement of NGAL
levels. Unfortunately, no studies have assessed the long-term
stability of NGAL at 80°C. However, the levels of plasma
NGAL observed and the strong association between NGAL and
outcomes in our study argue that there is sufficient stability to
preserve the analyte. Second, NGAL levels were only mea-
sured at 1 time point (baseline). Serial measurements of NGAL
may have provided additional risk stratification. Third, there is
the potential for some misclassification of hospitalizations
within the first 18 months of follow-up because of International
Classification of Diseases (ICD9) coding. Finally, this study was
limited to older women aged 70 years and over and may not
be generalizable to younger populations or older men.
Nevertheless, this study has several strengths including being
a well-designed, longitudinal community-based study with
14.5-year follow-up of clinical outcomes independent of self-
report, which is one of the largest studies with measurements
of plasma NGAL and long-term follow-up.
Conclusions
In conclusion, we have demonstrated that circulating NGAL is
independently associated with long-term CHD outcomes in
older women and may improve risk prediction in high-risk
older women.
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